Trump Administration’s New Requirements On Novavax’s COVID-19 Vaccine Could Sow Uncertainty About Other Vaccines

The AP (4/28, Neergaard, Perrone) reports the Trump Administration’s ongoing efforts to impose new requirements on Novavax’s COVID-19 vaccine is “sowing uncertainty about updates to other vaccines” in the industry. Novavax “said Monday that the Food and Drug Administration was asking the company to run a new clinical trial of its vaccine after the agency grants full approval,” even though the company has argued that its current shot remains “approvable.” The decision from the FDA comes “shortly after the agency’s longtime vaccine chief was forced out over disagreements” with HHS Secretary Kennedy. Observers are now expressing concerns that this new scrutiny may effect other COVID-19 vaccines as well as unrelated products, such as the influenza vaccine.